The Medical University of South Carolina, in collaboration with the National Institute of General Medical Sciences (NIGMS) and the COBRE in Neurodevelopment and its Disorders (CNDD), will soon initiate a clinical trial to evaluate Low Intensity Focused Ultrasound (LIFU) technology for Autism Spectrum Disorder (ASD). The study, listed as not yet recruiting, offers insights into the potential of medical devices in neurodevelopmental therapy for ASD.
In this article:
- What are the trial details?
- What is the study objective?
- Who is sponsoring the trial?
- FAQ
- Conclusion
- Disclaimer
- Link to the announcement
What are the trial details?
This clinical trial aims to assess the effectiveness and safety of LIFU technology as an intervention device for individuals with Autism Spectrum Disorder (ASD). LIFU is a non-invasive tool that uses targeted ultrasound waves to modulate brain activity, potentially unlocking new therapeutic pathways for neurodevelopmental conditions. However, details on recruitment status, timeline, and participant criteria remain unavailable as the study is currently listed as not yet recruiting.
What is the study objective?
The principal objective of the trial is to investigate the potential of LIFU as a device-based intervention for ASD. Autism Spectrum Disorder affects millions globally, characterized by challenges in communication, behavior, and social interaction. This trial may present significant advancements in addressing specific symptoms through targeted brain modulation without the need for invasive procedures.
Who is sponsoring the trial?
The Medical University of South Carolina spearheads the initiative with support from the National Institute of General Medical Sciences (NIGMS) and COBRE in Neurodevelopment and its Disorders (CNDD). Such collaborative efforts between leading institutions and federal organizations underscore the credibility and significance of this potential breakthrough in ASD management.
FAQ
- What is Low Intensity Focused Ultrasound (LIFU)?
LIFU is a medical device technology utilizing low-frequency ultrasound waves to affect brain activity, providing a promising method for non-invasive neurological interventions. - Why is LIFU being studied for ASD?
ASD involves neurodevelopmental challenges, and LIFU could offer a targeted, non-invasive approach to address specific dysfunctions in neural pathways. - Who will be eligible for the trial?
Participant criteria have not yet been announced. Please refer to the ClinicalTrials.gov listing for future updates. - When will recruitment begin?
The trial is listed as “not yet recruiting,” with no exact start date confirmed.
Conclusion
The upcoming LIFU clinical trial marks a pivotal step in exploring device-based therapy for Autism Spectrum Disorder. Regulatory and clinical professionals should monitor the study’s progress for implications on future developments in ASD therapies. This innovation has the potential to redefine non-invasive interventions for neurodevelopmental disorders.
Disclaimer
This article is intended for informational purposes only and does not constitute legal or clinical advice. Always refer to official trial documentation and regulatory authorities for validated information.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07225322?term=medical+device